Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Investor webcast on Tuesday, October 10th at 8:00 a.m. ET to present clinical data.  

Akero Therapeutics (AKRO) will hold an investor conference . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.